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ABSTRACT
Objective: a strong association has been observed between
celiac disease, generally its silent clinical form, and autoimmune
disorders. A potential correlation with inflammatory bowel disease
has also been suggested. Anti-tissue transglutaminase antibodies
have been detected in Crohn’s disease. We investigated the preva-
lence of celiac disease in patients with autoimmune diabetes and in
Crohn’s disease patients and also evaluated the correlation between
anti-transglutaminase antibody positivity and the clinical status of
these diseases.
Methods: anti-tissue transglutaminase and anti-endomysium
antibodies were assessed by enzyme-linked immunosorbent assay
and indirect immunofluorescence, respectively. Upper digestive
endoscopy and duodenal biopsy were indicated for cases with posi-
tive serology.
Results: anti-transglutaminase antibodies were detected in five
diabetic patients (prevalence of 11.1%), only one serum sample was
positive for IgG isotypes. Nine of thirty-three patients with Crohn’s
disease had low positive levels for IgA anti-transglutaminase. Anti-
endomysium antibodies were detected only in celiac patients. Celiac
disease was confirmed in all diabetic patients submitted to duodenal
biopsies who presented both anti-transglutaminase and anti-endo-
misyum antibodies positivity. In Crohn’s disease, its clinical status
and the diagnosis of celiac disease were not associated with positive
anti-transglutaminase result. 
Conclusions: the prevalence of celiac disease was high in dia-
betic patients. Anti-tissue transglutaminase antibodies were sensitive
and specific markers of celiac disease in this diabetic group, while
these antibodies were of limited value for celiac disease screening
in patients with Crohn’s disease.
Key words: Anti-tissue transglutaminase. Celiac disease. Crohn’s
disease. Diabetes mellitus.
INTRODUCTION
Celiac disease is an enteropathy that is triggered by an
environmental stimulus (gluten) in individuals with a genet-
ic predisposition. The histological and clinical character-
istics of celiac disease are defined by the intensity of the
immune response which, in turn, is influenced by the inter-
action between the environmental factor and genetic back-
ground (1,2). 
The advent of sensitive and specific serological tests has
facilitated the diagnosis of celiac disease and its atypical
clinical forms, and even the identification of asymptomatic
individuals (3,4). A strong association has been observed
between celiac disease, generally its silent clinical form,
and autoimmune disorders (5). Studies have shown that
inflammatory bowel disease is more common in celiac
patients than in the general population (6,7), although some
researchers have contested this affirmation. The contradic-
tory results were attributed to genetic background and/or
environmental factors (8). 
Anti-endomysium antibodies are a specific marker of
celiac disease. Since transglutaminase has been recognized
as the main antigen of anti-endomysium antibodies (9),
tests have been developed for the detection of anti-tissue
transglutaminase (anti-tTG) antibodies. These tests were
found to be highly sensitive for the diagnosis of celiac dis-
ease. However, a high rate of false-positive results has been
reported. The use of purified or recombinant human antigen
has improved the specificity of the test (10,11). Transglu-
taminase is a multifunctional protein normally expressed
in endothelial cells, smooth muscle cells and mesangial
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cells. This enzyme plays an important role in apoptosis and
has been reported to be actively involved in the wound heal-
ing process (12,13).
Anti-tTG antibodies have been identified in inflamma-
tory bowel disease, suggesting a low specificity of these
antibodies for the diagnosis of celiac disease. This obser-
vation was attributed to tissue lesions or to the inflammatory
activity presented in patients with inflammatory bowel dis-
ease (14,15). 
IgG antibodies against tTG have been detected in autoim-
mune diseases not associated with celiac disease (16,17). 
Based on the hypothesis that celiac disease is associated
with autoimmune diabetes and Crohn’s disease or that the
occurrence of anti-tTG antibodies, especially IgG, is trig-
gered by an autoimmune condition, we assessed IgA and
IgG anti-tTG antibodies using specific human tTG antigen.
The focus this study was the diagnosis of celiac disease
in patients with autoimmune diabetes and in a group of
patients with Crohn’s disease. We also evaluated the cor-
relation between anti-tTG positivity and the clinical status
of these diseases in those patients whose celiac disease was
not diagnosed.
PATIENTS AND METHODS
Patients
The study was approved by the Ethics Committee of our
institution and informed consent was obtained from all
patients. 
Celiac disease was investigated in 45 consecutively
selected patients with autoimmune diabetes (18). Twenty-
four of the patients were female, the median age was 18
years (range: 14 to 26), and the median duration of diabetes
was 8 years (range: 1 to 14).
Thirty-three patients with Crohn’s disease were diag-
nosed according to clinical, radiological, endoscopic and
morphological criteria. Eighteen women and 15 men with
a median age of 42 years (range: 18-72) and a disease dura-
tion of 9 years (range: 1-24) were studied. Inflammatory
activity was assessed using the Harvey-Bradshaw simple
clinical index (19) and by laboratorial tests (serum albumin)
(20). Disease location and behavior were classified accord-
ing to the Montreal classification for Crohn’s disease (21).
Serological tests
The patients were submitted to the investigation of anti-
human tTG (IgA and IgG) and anti-endomysial (IgA) anti-
bodies. All serum samples were tested in duplicate. IgA
and IgG anti-human tTG antibodies were measured by
enzyme-linked immunosorbent assay using a commercial
kit (Quanta LiteTM, Inova Diagnostics, Inc., San Diego, CA,
USA) according to manufacturer instructions. Absorbance
was read at 450 nm. Antibody titers > 20 arbitrary units
(AU)/mL were defined as positive. IgA anti-endomysial
antibodies were detected by indirect immunofluorescence
using monkey esophagus as substrate (ImmuGloTM kit,
Immco Diagnostics, Buffalo, NY, USA) according to man-
ufacturer instructions. A titer > 1:10 was considered to be
positive. 
Upper digestive endoscopy and histological analysis
Upper digestive endoscopy and duodenal biopsy were
indicated for cases presenting positive serology. Excluded
from this phase of the study were diabetic patients with
autonomic neuropathy and patients regularly taking nons-
teroidal anti-inflammatory drugs.
Biopsies were obtained from the distal duodenum, fixed
in 10% formalin, processed for paraffin embedding, and
stained with hematoxylin-eosin. All slides were examined
under a light microscope at 400X magnification under the
supervision of an experienced pathologist in the diagnosis
of celiac disease. 
The number of intraepithelial lymphocytes (IELs) and
epithelial cell nuclei was counted in an uninterrupted
sequence of superficial epithelium, for a total of 300 epithe-
lial cells. The number of lymphocytes found, excluding
those crossing the basement membrane, was expressed as
the proportion per 100 epithelial cells. Infiltrative lesion
(type 1 lesion) was defined as IELs density higher than 30
lymphocytes/100 epithelial cells.
The histological alterations observed in the duodenal
mucosa that corresponding to those described for celiac
disease were classified according to the criteria adopted by
the North American Society for Pediatric Gastroenterology,
Hepatology and Nutrition and by the Working Group of the
United European Gastroenterology Week (22,23). 
Statistical analysis
Data are expressed as mean or median and range. Quan-
titative variables were compared by the Mann-Whitney U
test. Differences in the distribution of categorical data were
compared using the chi-square test or Fisher’s exact test,
when required. A p value < 0.05 was considered to be sta-
tistically significant.
RESULTS
All patients ingested gluten regularly.
Serological tests
Anti-tTG antibodies (IgA) were detected in four diabetic
patients, with a median titer of 95.9 AU/mL (48.3 to 130).
These cases also tested positive for anti-endomysial anti-
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bodies, with a median titer of 1:40 (1:40 to 1:240). Only
one serum sample was positive for IgG anti-tTG, with a
titer of 85.5 AU/mL. This sample belonged to a diabetic
patient who was IgA deficient (serum level < 7 mg/dL). 
Nine of the 33 patients with Crohn’s disease were pos-
itive for IgA anti-tTG antibodies, with a mean titer of 25.54
± 5.23 AU/mL (Fig. 1). Anti-endomysial antibodies were
not detected in any of these patients. Two serum samples
presented homogeneous fluorescence of the whole myofib-
ril, suggesting the presence of smooth muscle antibodies
at low levels.
Upper digestive endoscopy and histological analysis
Fourteen subjects were selected for upper digestive
endoscopy. Three of the Crohn’s disease patients refused
to undergo the procedure and were excluded from the study. 
All diabetic patients who were submitted to endoscopy
presented histological alterations compatible with those
described for celiac disease and received a gluten-free diet.
The mean density of IELs in the duodenal biopsies of these
patients was 50.8 ± 18.14 lymphocytes/100 epithelial cells. 
The duodenal biopsies of Crohn’s disease patients
showed a preserved villous architecture. The mean density
of IELs was 12.17 ± 6.59 lymphocytes/100 epithelial cells
and this was significantly different from that of celiac dia-
betic patients (p = 0.04).
No association was observed between anti-tTG positivity
and clinical status of the Crohn disease (Tables I and II).
DISCUSSION
Transglutaminase is an enzyme widely found in human
organs, which is involved in various physiological processes
such as extracellular matrix formation, apoptosis and intesti-
nal mucosal healing (13,24). 
Type 1 diabetes mellitus is an organ-specific autoimmune
disease resulting from the destruction of insulin-producing
pancreatic beta cells. Glutamic acid decarboxylase (GAD65)
is a beta-cell autoantigen. T cells have been shown to play
a critical role in the destruction of beta cells, with the con-
tent of apoptotic bodies coming in contact with the immune
system, which leads to an autoimmune response (25). We
used autoantibodies to anti-GAD65 as a marker of autoim-
munity in the type1 diabetic patients studied here. No asso-
ciation was observed between the presence of the GADA65
and anti-tTG positivity (data not shown).
We found a significant increase in anti-tTG titers in dia-
betic patients with diagnosis of celiac disease. The absence
of anti-tTG antibodies in autoimmune diabetes not associ-
ated with celiac disease suggests that its positivity in celiac
diabetic patients is a fact that may not be related to autoim-
munity alone. 
In celiac disease, the sensitivity of IgG anti-tTG antibodies
is close to 100% in IgA-deficient patients (26). In the present
study, the only serum sample that tested positive for these
antibodies belonged to a celiac patient with IgA deficiency.
Table I. Anti-transglutaminase profile according
demographic and clinical features of Crohn disease patients
Patients characteristics Anti-tTG p
positive negative
Gender (F/M) 4/2 13/11 0.665
Disease duration (years)* 10 9 0.840
Albumin levels (g/dL)* 4.6 4.5 0.813
Inflammatory activity 0.309
Active 3 6
Inactive 3 18
Tabagism (y/n) 1/5 4/20 1.0
*median. F: female; M: male; y: yes; n: no.
Table II. Anti-transglutaminase profile according 
Montreal classification for Crohn’s disease patients 
that undergone duodenal biopsies
Anti-tTG p
positive negative
Age at diagnosis (yr) 0.290
Below 16 None 3
Between 17 and 40 5 14
Above 40 1 7
Location 0.213
L1 None 12
L2 2 5
L3 4 7
Behavior 0.375
B1 1 11
B2 1 4
B3 4 9
Fig. 1. Serum anti-tissue transglutaminase concentrations in diabetic patients
with celiac disease and in patients with Crohn’s disease (p = 0.003, Mann
Whitney test).
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We observed low positive levels of anti-tTG (IgA) in
patients with Crohn’s disease, whose duodenal biopsies
showed a preserved villous architecture. Several studies
have shown that the prevalence and serum levels of anti-
tTG antibodies depend on the degree of histological damage
in celiac disease (27,28). It is possible that the presence of
severe villous atrophy had been responsible for the higher
serum anti-tTG titers observed in diabetic celiac patients
when compared to Crohn’s disease patients.
Large numbers of villous IELs was described during an
episode of active Crohn’s enteritis (29). However, Wright
et al. (30) found a similar IEL density in the duodenum of
Crohn’s disease patients with normal radiographic and
endoscopic findings in agreement with our results. 
Di Tola et al. (15) reported a relationship between anti-
tTG positivity and Crohn’s disease activity, although the
degree of intestinal damage had not been described. No
such relationship was demonstrated in the present study.
This discrepancy might be due to differences in the criteria
used to define inflammatory activity in Crohn’s disease or
in the histopathological features.
Complications of diabetes mellitus such as autonomic
neuropathy classically occur in patients with long-term
disease. The knowledge that the presence of this motor
disorder may favor the occurrence of an inflammatory
process in the intestinal mucosa (31) led us to study
patients with recent-onset diabetes. The Crohn’s disea -
se patients in our study were older than the diabetic ones.
However, this demographic characteristic did not interfere
with the present results since anti-tTG antibodies have not
been reported to be related to age in adolescent and adult
patients (32).
Farrace et al. (14) demonstrated that tTG is released by
fibroblasts into the extracellular matrix in the intestine of
celiac patients. In the present study, anti-endomysial anti-
bodies were only detected in patients with celiac disease.
However, a homogeneous intracellular fluorescence pattern
was observed in two patients with Crohn’s disease. 
Antibodies reacting with components of the cytoskeleton
have been described in patients with inflammatory bowel
disease (33) and celiac disease. Pedreira et al. (34) found
an association between the presence of these antibodies and
the severity of gut injury in celiac patients. The identification
of cytoplasmic actin as an abundant glutaminyl substrate
for tTG in leukemia –derived human cell lines undergoing
apoptosis (35) suggests that intracellular transglutaminase
might be the antigen related to this fluorescence pattern.
Thus, the presence of anti-smooth muscle antibodies and
anti-endomysium antibodies might indicate a distinct anti-
genic expression patterns for tTG. Villous atrophy might be
necessary to trigger an increase of anti-tTG antibody titers
and the appearance of anti-endomysin in these diseases.
Further studies are still needed to investigate the relationship
between anti-tTG antibodies and duodenal villous atrophy
in Crohn’s disease in order to determine whether this pattern
of tissue injury is responsible for the elevated titers of these
antibodies.
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